In the study by Block et al., “Safety and Efficacy of Tenapanor for Long-term Serum Phosphate Control in Maintenance Dialysis: A 52-Week Randomized Phase 3 Trial (PHREEDOM)” (Kidney360 2021;2(10):1600–1610. DOI 10.34067/KID.0002002021), corrections are needed.
The authors have identified errors in the units used to describe the doses of sevelamer. The sentence, “For the safety control group, the median starting dose of sevelamer was 4800 g (six tablets) daily and median final dose at 52 weeks was 7200 g (nine tablets) daily,” should instead be listed as the following: “For the safety control group, the median starting dose of sevelamer was 4800 mg (six tablets) daily and median final dose at 52 weeks was 7200 mg (nine tablets) daily.”
In addition, the sentence, “There were also more pronounced mean reductions in serum phosphate concentration compared with placebo at all doses of tenapanor and in all subgroups (Supplemental Figure 3 and Supplemental Table 2),” should be corrected to the following: “There were numerically greater mean reductions in serum phosphate concentration compared with placebo at all doses of tenapanor and in all subgroups (Supplemental Figure 3 and Supplemental Table 2).”